Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
4(100.0%)
4Total
Phase 1(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07131202Phase 1Recruiting

A Study of FL115 in Combination With a PD-1 Antibody in Advanced Solid Tumors

Role: lead

NCT07131189Phase 1Active Not Recruiting

A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors

Role: lead

NCT06130722Phase 1Completed

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Role: lead

NCT07122414Phase 1Recruiting

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Role: lead

All 4 trials loaded